Summary
The National Eye Institute (NEI), part of NIH/HHS, is soliciting applications under its Translational Research Program for Therapeutics using the R61/R33 phased award mechanism. This program supports translational research aimed at developing therapeutics for eye diseases and vision disorders, explicitly excluding clinical trials. The R61 phase typically funds milestone-driven feasibility/development work, while the R33 phase supports more advanced translational development contingent on R61 milestones being met. This opportunity is currently forecasted, with an open date of September 9, 2025.